Valuence Merger I ^{Priced, Nasdaq: VMCAU}

We are a newly incorporated blank check company. Our objective is to identify, merge with, and partner with a business in Asia (excluding China, Hong Kong and Macau) that is expected to exhibit sustained, long-term growth, and value creation. We will not pursue or consummate our initial business combination with any entity with its principal business operations in China, Hong Kong or Macau. We intend to focus on companies within the following sectors: developing breakthrough technology in life sciences, including, but not limited to, oncology, anti-aging and chronic diseases, precision medicine, healthcare technologies, and synthetic biology; or developing and advancing a platform for sustainable technology, including, but not limited to, agriculture & consumer, enabling technologies, energy & power, materials & chemicals, resources & environment, and advanced transportation. In addition to our internal resources, our management team and Board bring together the sector expertise of CrystalBioSciences and the investment track record and deal flow of Credian Partners.